Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [14] Core Insights - The non-pharmaceutical sector is facing performance pressure in 2025 due to price reductions from centralized procurement, medical insurance cost control, and the closure of retail pharmacies. However, companies are leveraging overseas expansion and innovation to achieve growth [4][9] - For 2026, the domestic fundamentals are expected to improve, with companies seeking new growth points primarily through overseas expansion and innovation, particularly in insulin and medical devices [9] - The report highlights that the insulin market is stabilizing post-centralized procurement, with significant overseas opportunities for leading companies like Mindray Medical and Ganli Pharmaceutical [10][24] - The focus on innovation in traditional Chinese medicine and medical devices is expected to create alpha opportunities for individual stocks [9][11] Summary by Sections Non-Pharmaceutical Sector - The non-pharmaceutical sector is under pressure but has opportunities through overseas expansion and innovation. Insulin and medical devices are key areas for long-term growth [4][9] - Companies like Mindray Medical and Ganli Pharmaceutical are beginning to realize overseas revenue, indicating a significant long-term market potential [9] Biopharmaceuticals - The report prioritizes insulin, with ongoing attention to blood products and vaccines. The insulin market is stabilizing, and companies are focusing on innovation and business development [10][24] - The report notes that the insulin market in developed countries is valued at $13.2 billion, with significant growth potential in emerging markets [24] Traditional Chinese Medicine - The focus is on innovation and the basic drug catalog, which is crucial for accelerating drug sales and enhancing market presence [11][12] - The report anticipates a recovery in performance due to early flu outbreaks and emphasizes the importance of retail pharmacy sales [11] Medical Devices - The report indicates that the medical device sector is at a turning point, with overseas revenue for leading companies expected to exceed 50% in 2025 [12] - The report suggests focusing on low-value consumables and in vitro diagnostics as key growth areas [12] Vaccines - The vaccine sector is currently facing challenges, with price reductions and low demand impacting sales. However, there are ongoing developments in innovative vaccines that warrant attention [39][40] - The report highlights the importance of tracking clinical progress and market performance of major vaccine candidates [40]

Group 1: Core Insights - The pharmaceutical industry is entering a clear upward cycle with significant growth opportunities in innovative drugs and the innovation chain, driven by supportive policies and a global expansion trend [3][10] - The Chinese innovative drug sector is increasingly favored by international capital, with a record high of 149 transactions in 2025, accounting for 11% of global transaction numbers and 29% of total transaction value [10][37] - The introduction of commercial health insurance into the medical insurance negotiation process in 2025 is expected to diversify the payment system for innovative drugs, enhancing their market accessibility [10][37] Group 2: Innovative Drugs - The upward policy cycle supports innovation, with the latest round of drug procurement entering a new phase of quality-price balance, as seen in the 11th batch of centralized procurement [10][30] - The global patent cliff from 2025 to 2037 is projected to create a gap exceeding $300 billion, prompting multinational corporations (MNCs) to pursue business development (BD) and acquisitions to fill this gap [10][45] - Chinese innovative drugs are positioned to capitalize on this trend, particularly in areas such as second-generation immune-oncology (IO) and next-generation antibody-drug conjugates (ADCs) [10][50] Group 3: Innovation Chain - The innovation chain, including Contract Development and Manufacturing Organizations (CDMO) and Contract Research Organizations (CRO), is benefiting from both domestic and international demand, with CDMO orders showing a positive growth trend [12][12] - The overseas biopharmaceutical investment environment is improving, with a notable increase in funding as interest rates decline, which is expected to enhance the overall industry cycle [12][12] - The life sciences service sector is witnessing a recovery, driven by increasing domestic research demand and improved conditions for innovative drug development [12][13] Group 4: Market Opportunities - The domestic market for innovative drugs is projected to grow significantly, with over 400 innovative drugs approved since 2020, indicating strong internal growth potential [62][66] - As innovative drug companies transition to profitability, there is a potential shift in valuation methods from P/Peak Sales to PE, attracting broader investment interest [66] - Key companies to watch include AiLisi, Yunding Xinyao, and Kangnuo Ya, which are expected to benefit from the commercialization of innovative products [66]

Investment Rating - The report assigns a "Buy" rating for the company, marking it as the first recommendation [9]. Core Insights - The company has experienced short-term operational fluctuations due to the order rhythm in the special and communication industries. However, it is expected to return to mid-to-high-speed growth due to previous high R&D investments, new capacity releases, and a new round of equity incentives [2][5]. - The high-reliability special power supply market has significant growth potential, driven by trends in equipment electrification and emerging sectors like domestic large aircraft and commercial aerospace. As a leading domestic manufacturer, the company is poised to benefit [6][60]. - In the AIDC and communication sectors, the company is leveraging its deep expertise in high-performance power supplies to tap into the burgeoning AIDC power market, which is expected to yield substantial revenue growth [7]. Summary by Sections Company Overview - Established in 1997, the company focuses on high-efficiency, high-reliability, and high-power-density power products, particularly in aerospace, aerospace, and special high-grade power supply fields. It has developed a rich product portfolio and offers comprehensive solutions across multiple industries [5][18]. Market Trends - The high-reliability special power supply market is recovering steadily, with long-term positive trends. The demand for power supplies in domestic large aircraft and commercial aerospace is expected to expand significantly, with projected annual demand reaching 16.9 billion in the next 20 years [6][54]. - The AIDC and communication sectors are experiencing a boom driven by AI computing power, leading to increased demand for server power supplies. The global AI server power module market is projected to grow from $6.5 billion to $60.8 billion between 2025 and 2031 [7][28]. Financial Performance - The company has faced short-term revenue and profit fluctuations due to order volatility in the special and communication sectors. However, it has shown signs of improvement in the first three quarters of 2025, with revenue reaching 929 million, a year-on-year increase of 36% [27][29]. - The company's gross margin has fluctuated, with a projected gross margin of 40% for 2024 and 2025, reflecting the impact of product structure adjustments and increased R&D expenses [29][30]. R&D and Capacity Expansion - The company maintains a strong commitment to R&D, with a focus on developing core technologies and expanding its product offerings. It has accumulated 399 intellectual property rights, including 67 invention patents [35][36]. - New capacity projects across multiple locations are nearing completion, with significant contributions expected to revenue and production capacity by 2025 and 2026 [42][44]. Equity Incentives - The company has implemented multiple rounds of equity incentives to bind core employees, with the latest plan aiming for substantial revenue growth targets over the next three years [46][48].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a total revenue of 13.059 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 29.8%. The net profit attributable to shareholders was 552 million yuan, up 41.54% year-on-year, while the net profit excluding non-recurring items reached 506 million yuan, growing by 48.2% [2][4]. - In Q3 2025 alone, the company achieved a revenue of 5.48 billion yuan, marking a 50.45% increase year-on-year, with a net profit of 217 million yuan, which is a 61.82% year-on-year growth [2][4]. - The company has seen a steady increase in sales volume of lithium battery cathode materials, reaching 99,900 tons in the first three quarters, a 40.41% increase year-on-year. The sales of lithium cobalt oxide reached 46,900 tons, up 45.38% year-on-year [11]. Summary by Sections Financial Performance - The company’s total revenue for 2025 is projected to be 17.166 billion yuan, with a net profit forecast of 1.049 billion yuan for 2026 [15]. - The gross profit margin is expected to improve, with a forecast of 10% for 2026 [15]. Business Outlook - The company is focusing on the stable growth of its main business, with expectations of benefiting from the technological iteration in AI smartphones, which may enhance its market share [11]. - The solid-state battery segment is being actively developed, with positive progress in the validation of new cathode materials and electrolytes [11]. Market Position - The company is positioned to benefit from the rising cobalt prices, which are expected to further enhance profitability [11]. - The competitive landscape in the industry is intensifying, but the company’s strategic initiatives in high-nickel cathode materials and low-cost production methods are anticipated to sustain its competitive edge [11].

[Table_Title] 如何看 2025 年 11 月消费数据？ 联合研究丨行业点评 %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 11 月份，社会消费品零售总额 43898 亿元，同比增长 1.3%。其中，除汽车以外的消费品零售 额 39444 亿元，增长 2.5%。1—11 月份，社会消费品零售总额 456067 亿元，增长 4.0%。其 中，除汽车以外的消费品零售额 411637 亿元，增长 4.6%。 分析师及联系人 [Table_Author] 李锦 赵刚 高伊楠 SAC：S0490514080004 SAC：S0490517020001 SAC：S0490517060001 SFC：BUV258 SFC：BUX176 SFC：BUW101 于旭辉 蔡方羿 董思远 SAC：S0490518020002 SAC：S0490516060001 SAC：S0490517070016 SFC：BUU942 SFC：BUV463 SFC：BQK487 陈亮 SAC：S0490517070017 SFC：BUW408 请阅读最后 ...

行业研究丨点评报告丨软件与服务 [Table_Title] 国内首个太空计算实验室成立，关注我国太空算 力产业进展 报告要点 丨证券研究报告丨 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_Summary] 12 月 12 日，上海交通大学与国星宇航举行签约仪式，共同建设国内首个太空计算联合实验室。 此次合作将充分发挥上海交通大学在人工智能等前沿领域的创新优势，以及国星宇航率先完成 AI 智算星座组网的探索优势，致力于打造技术领先、自主可控的太空计算网络，推动形成具有 全球影响力的太空计算产业集群。建议关注：1）卫星制造商以及发射服务提供商；2）耐空间 环境的算力硬件供应商；3）太空算力运营商。 分析师及联系人 [Table_Author] 宗建树 陈耀文 SAC：S0490520030004 SAC：S0490525070002 SFC：BUX668 软件与服务 cjzqdt11111 [Table_Title 国内首个太空计算实验室成立，关注我国太空 2] 算力产业进展 [Table_Summary2] 事件描述 12 月 12 日，上海交通 ...

Group 1 - The report indicates that the manufacturing sector is expected to stabilize, with overseas retail remaining robust and inventory levels in the industry and brand sectors returning to health. A shift in inventory cycles is anticipated, which could lead to either proactive replenishment or passive destocking phases, depending on demand changes [4][7][8] - Domestic retail sales have shown signs of recovery since August, supported by favorable policies such as tariff reductions and measures to boost domestic demand. This trend is expected to continue into next year, increasing the likelihood of a transition to proactive replenishment or passive destocking phases [4][9] - The report suggests focusing on high-elasticity profit recovery stocks in the A-share market, while emphasizing the need for certainty in brand retail, particularly in the Hong Kong market where short-term pressures persist [4][10] Group 2 - The analysis reveals that the textile and apparel industry has slightly underperformed the broader market this year, with the textile manufacturing index rising by 13.3% compared to a 5.3% increase in the brand apparel index as of December 12, 2025 [23][32] - The report highlights that the retail sector has shown steady recovery, with a year-on-year increase of 6.3% in retail sales for clothing and textiles in October 2025, although export figures have been weak, reflecting a decline of 9.1% in textile exports [21][23] - The report emphasizes the importance of understanding the inventory cycle and the potential for significant catalysts in head sports manufacturing orders and stock prices as demand shifts [7][8][9]

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Views - The company has been officially included in the Hong Kong Stock Connect, which accelerates its overseas expansion [3]. - In Q3 2025, the company achieved revenue of 11.975 billion yuan, representing a year-on-year increase of 18.84% and a quarter-on-quarter increase of 13.67%. However, the net profit attributable to the parent company was 380 million yuan, down 17.33% year-on-year and down 10.65% quarter-on-quarter [3][8]. - The company completed its H-share issuance and was listed on the Hong Kong Stock Exchange on November 17, 2025, marking a key step in its strategy for technological diversification and global development [8]. Financial Performance - The company’s Q3 2025 financial data shows a gross profit margin of 12%, with total revenue projected to reach 40.223 billion yuan in 2027, increasing to 66.928 billion yuan by 2027 [13]. - The net profit attributable to the parent company is expected to reach 2.2 billion yuan in 2026 and 2.775 billion yuan in 2027 [13]. - The company’s financial expenses in Q3 2025 were 345 million yuan, reflecting an increase due to exchange rate impacts [8]. Market Position and Outlook - The company’s three-element precursor materials and cobalt oxide materials are expected to continue growing, with growth rates anticipated to exceed industry levels [8]. - The utilization rate of phosphate iron has significantly improved, and profitability is expected to show improvement, contributing to incremental performance [8]. - Nickel resource production is expected to remain stable, with potential for improved profitability if nickel prices recover [8].

[Table_Title] 谁来接棒托底内需？ 丨证券研究报告丨 中国经济丨点评报告 ——11 月经济数据点评 报告要点 [Table_Summary] 从 11 月经济和政策信号来看，一方面是过去经济增长的结构性支撑在持续转弱，但另一方面， 政策对短期波动的定力不减反增：2025 年中央经济工作会议首次提出（将）"存量政策和增量 政策纳入宏观政策取向一致性评估。"12 月政治局会议首次提出"坚持内需主导"，均体现出在 政策端对于加速培育新业态发展的决心进一步增强。我们认为，在人口老龄化、地方化债的背 景下，地产基建投资或难有显著改善，"反内卷"则抑制着制造业投资的弹性，这意味着投资的 上行空间较为有限，叠加耐用品消费明显承压，服务消费料将成为 2026 托底内需的主要抓手。 分析师及联系人 [Table_Author] 于博 SAC：S0490520090001 SFC：BUX667 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com ——11 月经济数据点评 [Table_Summary2] 事件描述 2025 年 12 月 15 日，国家统计局公布 11 月经济数 ...

行业研究丨深度报告丨电气设备 [Table_Title] 新章与更序 ——电新行业 2026 年度投资策略 [Table_Summary] 复盘过去 6 年电新行业股价走势，我们认为作为典型的成长性行业，"需求"是最核心驱动要 素，同时"价格"贡献额外弹性。2026 年作为十五五第一年，我们认为电新行业底层需求驱动 因素出现变化，有望催动新一轮需求景气周期：1）宏观层面，新能源发展方向不变，人工智能、 具身智能产业趋势明确；2）中观层面，新能源转向高质量发展，消纳逐步成为核心，人工智能 将拉动全球电力需求开启新的增长；3）微观层面，电新各细分赛道均有不同程度受益。 分析师及联系人 [Table_Author] 邬博华 曹海花 司鸿历 SAC：S0490514040001 SAC：S0490522030001 SAC：S0490520080002 SFC：BQK482 SFC：BVD284 叶之楠 袁澎 王耀 SAC：S0490520090003 SAC：S0490524010001 SAC：S0490524120006 任佳惠 喻亨一 周圣钧 SAC：S0490524070005 SAC：S049052503 ...